acquisition currency see medium of exchange
activist playbook 396, 397
see also investors, activist; stockholder, activism
agency costs 53, 186, 188, 305, 402, 410
managerial 69, 70, 188, 402
multi-task principal-agent model 406–7, 409–10
reducing 325, 331
agreements see contracts
American Stock Exchange 360
Angel's List 123
antitrust see also trusts
clearance 53
contracts and 52
regulation 2, 16, 17–19, 53, 344
enforcing 20
reviews 49
risk 57–8
trustbusters 17, 18
appraisal see also stockholder
actions 335, 336–7
structure of 338, 341–2
arbitrage 335, 438
criticism of 341
deterrence mechanisms 346–7
deterrence value of 335, 344–9
limitations 350–51
fair value 336, 337–8, 348–9
funds 341
judicial expertise 349
petitions 338–9, 342
counseled 339
repeat 341
value of 340
rarity of 341
rights 7, 101, 107
backlash against 342–4
protecting 106, 337
restricting 102–3
second-best, as 347, 351
stockholder 7, 335
limitations 337
procedural requirements 337
remedy, as 335, 336–8
arbitrage
appraisal 335, 438
criticism of 341
rise of 341
arbitrageurs 7, 341, 403
limitations on 403–4
pricing theory 400
regulatory 26
short-termism and 411
arms-length
bargaining 278
transactions 289, 296–7, 329
valuation 129
assets see also asset sales; valuation
deal currency, as 34
earnings potential of 158–9
intangible 32, 211
lockups 235, 254
partial acquisitions, in 46, 51
purchase agreements 223
tangible 32
transfer of 32, 34, 41
reallocations of 73
tax 181, 386
true value 159, 162–3, 166, 171–2
valuation of 34, 155
asset sales see also equivalence; Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc.
divestitures, on 72
equivalence in 100–101, 104–5, 106–7, 108
majority approval in 108
no appraisal rights in 103
re-characterizing 102, 107
Revoln duties, and 110–14
successor liability in 104–6

Barnard, Judge G. 14, 16
beneficial ownership 353, 363–5, 368–9, 385, 386
disclosure 435–6
best price 226, 231, 345–6
directors’ duty to achieve 226–7, 265
institutional investors and 367
bidders
Canada, in 428, 438, 440
disclosure obligations 359
deterring 362
first-in (initial) 218, 224, 255
hostile 292, 320, 321, 419, 427
intervening 237
multiple 267, 345–6
poison pills, and 202
single 266, 267, 348
staggered boards, and 205, 208
stock-for-stock exchanges, in 359
tender offers, and 57, 358, 360
shareholders, sources of value for 67–74
white knights 182, 250, 265
blackout periods 391
board of directors
see also best price; business judgment rule; directors
activist designees on 388–91
authority 280, 282
board advocates 201
business judgment 109, 110, 114, 393–4
composition 50
conflict of interest 93, 141, 346
court deference to 2, 5, 83, 84, 90, 226, 270
decisions 83–4
defenses see defenses
DGCL policy on 391, 394
discretionary power 237, 347–8
duties 109, 265, 280
fiduciary obligations 5, 226, 319
best price 226–7, 265, 266, 345–6
final period problem 109–10
influences on 329
insulating on 304, 404, 405–6, 407
proxy contests see proxy contests
recommendation covenants 221–2, 224
Revoln duties 110–14, 226–7, 269
scrutiny of 2, 5
staggered see staggered boards
target 22, 267, 288, 291, 296, 320–21
transaction approval 32, 114, 285, 296
unitary 200, 204
break fees see deal protection devices
Brokaw Act 368–9
business judgment rule 2–3, 296, 330
see also board of directors; directors;
freezeouts; self-dealing
Canadian 434
defense 2, 5, 6, 84, 90, 226, 268, 321
not applying 111
freezeouts, in 6
insulating directors 84
invoking 94
justification for 89
modern 84, 90, 97
takeovers, in 90–91
controlling stockholder transactions 85, 88, 93–5, 97
hostile takeover defense 91–3
stockholder ratification 95–7
threshold requirements 91
traditional 83–4, 85
abstention doctrine, as 87–8
not applying 111
presumption, as 85–6, 112
self-dealing, and 109
standard of care, as 86–7
substantive rule of law, as 88–90
buyer–seller, statutory distinction 108, 109
buyouts
debt-financed 59
leveraged see leveraged buyouts
management (MBOs) 23, 329, 330
minority 285
private equity-led 61
cash-out mergers see freezeouts
Canadian M&A, comparison with U.S. advance notice by-laws 431
British Columbia Securities Commission 419
business combinations (freeze-out mergers) 437–8
amalgamation squeeze 438–9
Canada Business Corporations Act (CBCA) (1985) 422
Canadian Securities Administrators 420, 423, 440
Competition Act (1985) 421
compulsory acquisitions 437–8
corporate law 421–2
directors’ duties 431–4
disclosure 428
beneficial ownership 435–6
early warning threshold 436
fair value 437
Hart-Scott-Rodino Antitrust Improvements Act (1976) 421
hostile takeovers, favourable to 420, 421
Income Tax Act (1985) 421
Investment Canada Act (1985) 421
judiciary, and 423
’Just Say Slow’ regime 441
National Instrument 62-104 442
Ontario Securities Commission 439
poison pills 434–5, 441–2
pro-investor approach 419
proxy rules 419, 420, 429–30
exemptions from 430
reform 419–20
Securities Commission 442
securities regulation
exclusively provincial 423, 427
takeover bid rules 424
share acquisitions 424–5
amalgamation 425
reorganization 425
statutory plan of arrangement 426–7, 436
takeover bid 427–9, 436–7
shareholder activism favourable to 420, 421
rise in 429
shareholder rights 430, 431
permitted bids 441
staggered boards 430
takeover regulation 420, 427–9
10-day extension requirement 440
equal shareholder treatment 428
mandatory bid period 428
mandatory disclosure requirements 428
minimum deposit period 440–41
minimum tender requirement 428, 440
reforms 440–42
US distinction 419, 420–24, 429, 431, 442–3
capital
asset pricing model (CAPM) 399–400
equity 283
expenditure 42, 72
global 25
human 20–21, 70
investment 362
liquidity 73
markets 13, 26, 366
Canadian 424
efficiency see market efficiency
external 71
internal 71
modern 366–9
minority, reduced access to 295
stock 143
structure 147
venture see venture capital
capitalization 131
fully diluted 130, 131, 134, 135, 146
market 398, 436
pre-event 69
representations 456
cash flow 149
discounted 399, 400
analysis 403, 459
free 69, 70
future 8, 125, 348
rights negative 194
/voting rights link 192–3, 194
certainty equivalent (CE) 148–9
Clayton Antitrust Act (1914) 17, 19
Coase theorem 117
coercion 95, 228, 248
anti-coercion conditions 293
entire fairness review, and 288
excessive termination fees and 324
company
bylaws 32
advance notice 380–84
amendments 32
enforcement of 381–2
fee-shifting 306
forum-selecting 306
charters 32, 200
amendments 32, 67, 76
poison pills in 187
preferred stock preferences in 128
company law see corporate law
compensation
committees 383
executive 205, 346, 383, 406, 407, 411
controversy 371
complex pricing 39, 45, 53
confidentiality agreements 33, 224, 390
see also contracts
conflicts of interest 320
analysis 273
business judgment rule and 94, 321
inherent 91–2
investment banker 245, 258–9
conglomerates 13, 20–21, 24, 71, 216, 356
see also merger waves; oligopolies
diversification 357–8
divestitures 21–2, 72
revival of 26
consideration
additional 155, 162–3
cash 175, 176
earnouts, in 50, 172–6, 174–5
fair value 7
issues over 172–6
stock as 112–14, 157, 173–4
transaction 3–4
transfer of 34
valuation 34
consolidations 16–17, 24, 425
see also roll-ups
continuation of business doctrine 107, 110
contract law 52
contracts
see also confidentiality; deals;
defences; dispute resolution;
memorialization; specification;
transactions
affiliate letters 33
ancillary issues 34
anti-sandbagging clauses 42
articles 38–9
closing conditions 49, 50, 255, 257, 285
collateral 33–4, 51
complexity of 32
conditions 43
confidentiality 33, 224, 390
consideration see consideration
core 29–30, 35, 60
covenants 39, 42–3, 52
interim 42, 50
negative 42, 50, 62
processing 43
disclosure schedules 41
dispute resolution 31–2, 34–5, 51–2, 59–60
earnout clauses 58–9
exclusivity agreements 33
financing agreements 33–34
further assurances 47
general, purposes of 30–31
indemnities 41, 48, 53, 454
joint defense agreements 33
legal requirements 31–2, 33
legal transplants 445–7
lending agreements
letters of intent see letters of intent
lock-up options 33
material adverse change clauses
(MACs) 37–8, 48, 51, 56, 61, 255–8
miscellaneous provisions
moral hazard see moral hazard
non-disparagement agreements 393
non-reliance clauses 42, 52
ownership, effects of on 52–5
patterns of practice 35–6
Index 469

post-closing covenants 42, 53
preliminary agreements 33, 52, 60
private target 53, 54, 60, 453–60
pro-sandbagging clauses 48, 61
public target 38, 53, 54, 59
purposes of 31–5, 44
  business specification 45–7
  control 50–51
  dispute resolution 51–2
  information sharing 50–51
  price specification 47–8
  process management 34, 49
  risk allocation 48, 218–19, 453
  risk sharing 48–9, 60
  service provision 51
  structural specification 45
recitals 39, 45
regulation, effects of on 52–5
representations 39, 41, 48, 50, 453–4
  ‘10b-5 rep’ 41–2
  fundamental 41
schedules 50
  cross-referencing 46
disclosure 41
specification see specification
standstills 33, 52, 224, 393
support agreements 33
termination 38–9, 43, 49, 51, 232, 253, 254
  break fees 56–7, 217, 219, 220, 222, 323–4
  reverse break fees 57–8, 223
  rights 37, 50, 51
terms see terms
voting agreements 33, 223–4
warranties 50, 453–4, 456–7
corporate control
  market for 66–77, 207
  sales of 111, 113
corporate duties to third party
  stakeholders 407
corporate finance/economic theory
  398–400, 408
corporate governance 38, 53
  see also business judgment rule
  1960s 354–9
  activism 412
  advance notice bylaws 380–84
  evolution of 365–71
  priorities 207

Securities Act (1933) see Securities Act (1933)
Securities Exchange Act (1934) see Securities Exchange Act (1934)
type of 379
Williams Act see Williams Act (1968)
corporate law 32, 52
  Canadian 421–2
  form over substance, elevating 3
corporate purpose 264, 278–83
corporate raiders 22, 202, 248, 353
  –activist investors comparison 397
tender offers and 352–3, 357, 367
courts
  deference to directors 2
  judicial expertise 349
  judicial opinions 5
credit 25, 26
creditors
  final period problem and 110
  protection 110
  rights 104–5, 107, 110
  risk management 110
  –shareholders, differences in
treatment of 106–8
creeping takeovers 385, 387–8, 452
cross-border transactions see globalization; transactions
deal defences see defenses
deal points 36, 258, 459
deal protection devices see also business judgment rule;
  contracts; judicial opinion
  asset purchase agreements 223
  board recommendation covenants 221, 224
  break fees (termination fees) 219, 222, 323–4
collateral provisions 222
  confidentiality agreements 224
  crown jewels strategy 223
custody 236
  enforceability 236–7
  favouring buyers 237–8
  fiduciary out 224–5, 236, 255
  force-the-vote provisions 221–2, 224
  future of 235–8
go-shop provisions 220
information rights 223
insurance, as 218–19
judicial opinion on 253–5
jurisprudence see jurisprudence
lock-up 253, 254
creep 235–6
macroeconomic factors affecting 217–18, 223
market 236
matching rights 221–2
no-shop provisions 220, 253
no-talk provisions 220, 253
problematic, as 226
rationale behind 218
standstill provisions 224
stock options 223
termination fees 253, 254, 323–4
reverse 222, 223
topping fees 222
top-up options 223
validity of 226, 229
value of 230
negotiating 231
settlement 233–5
stockholder 231–3
variation within 222, 225
voting agreements 223–4
walkaway provisions 222
deals
see also contracts; transactions
currency 34, 37, 47, 60
pricing 60, 61, 294
private target 50, 53, 55, 59, 60
protecting see deal protection devices
public target 38, 53, 55, 59, 60
decoupling 193, 194
de facto mergers 100, 106
see also equivalence
doctrine 107, 110
equal dignity, and 102–4
defenses
see also poison pills; staggered boards; voting
appraisal see appraisal
corporate myopia, and 190–91
discriminatory 248–9
employee stock ownership as 192
empty voting, and 191–4
golden parachutes 22, 216, 320, 370
hostile takeover 91–3
joint defense agreements 33
levels of 186–9
poison pills 181–4, 202–3, 249–51
staggered boards 184–6, 187–8,
191–2
super-majority voting provisions 370
takeover 21, 22
two-tier tender offers, against 248
Delaware
see also judicial opinions; litigation
judicial expertise in 349
law 5, 229, 251, 320–21, 350, 377,
419, 438
advance notice bylaws in 380–84
class actions, on 324, 328
corporate purpose, on 280, 282
entire fairness scrutiny 329
equivalence, and 100–14
M&A contracts choosing 59
officer liability, on 277
public target deals and 55
takeover defences, on 345
Delaware General Corporation Law
(DGCL) 101, 116
Section 102(b)(7) 391
Section 144 96–7
Section 146 221
Section 251 114
(h) 337, 438
Section 253 437
Section 262 336
Section 271 114
(a) 107
Department of Justice (DOJ) 17
deregulation 71–2
Asia, in 26
developing nations’ entry to market 26
derivatives 193–4, 368–9
directors
see also board of directors; business judgment rule; fiduciary duties;
staggered boards
activist-supported 388–90
confidentiality, and 389, 390–91
blockholder 389
conduct 386
constituency 389
duties
asset sales, in 112–13
Index 471

sale of corporate control, in 113
fiduciary duty of care 5, 52, 89, 228, 389
independent 93, 264, 275, 277, 445
special committees (SC) 252, 285, 286, 287, 292, 299
power, primacy of 203
scrutiny of 2, 5
terms 4
disclosure
see also investors, protection for;
tender offers; Williams Act
avoiding 193
beneficial ownership 435–6
blockholder 435–6
confidential information 33, 389
full and fair 252
investment banker conflicts, of 258–9
mandatory requirements 32, 42, 365, 370–71, 428
non-only settlements 6, 279, 305, 314–15, 322–3
schedules 41, 359
tender offers and 352–4, 359
dispute resolution 31–2, 34–5, 51–2, 59–60
Indian M&A, in 459–60
dissolution 3, 105–6, 269
diversification 71, 72, 75, 357–8, 399
managing risk 20, 109–10
Dodd Frank Wall Street Reform and
Consumer Protection Act 368
dot.com bubble 24–5
Dow Jones Industrial Average 354
due diligence 50, 161, 453, 456–8
earnings before interest, taxes,
depreciation and amortization see EBITDA
earnouts 3–4, 58–9, 154–5, 176, 454–5
see also information, asymmetry
consideration in 172–6
implications 164–5
equilibrium selection 165–6
limitations on earnout size 168–9
sensitivity to signal accuracy 166–8
information asymmetry and 156–7
transactional failure 158–61
post-closing issues 155–6
‘lemons’ problem 164
moral hazard see moral hazard
valuation differences and 155, 157–8
EBITDA 155, 162, 171–2
economies of scale 20–21, 24, 30, 72
see also mega-deals
effective negative control 387–8
efficient capital market hypothesis
(ECMH) see market efficiency
employees
third party stakeholders, as 407
interests diverging from shareholders 409
empty voters 192–3
see also defences; voting
enhanced scrutiny 226–7, 269–71, 272, 292, 321
etire fairness reviews 251, 329–30
avoiding 6, 288–9
coercion and 288
fairness opinions 246–8
freezouts, in 287–8, 289, 292–3, 296–7, 300
tender offers, in 291, 292–3
unified approach to 289–90, 297, 299, 300–301
equity
financing tool, as 24
markets 366
collapse (2000) 24
private see private equity
securities 24, 126, 336, 363, 364, 365, 428
equivalence 99
see also de facto mergers
asset sales, in 100, 104–5
beta sensitivity and 108–9, 117
de facto mergers, in 102–4
economic 116–17
equal dignity doctrine 103, 107–8, 110
limitations 114–17
statutory mergers, in 100–101
stock sales, in 100
substantive 106–7
Erie Railroad war 13–16
estimation issues 74–5
escrows 39, 51, 60, 454, 457–8
exclusivity agreements 33
see also contracts
executive compensation 205, 346, 383, 406, 407, 411
expected utility theory 148
fair value 7, 337–8, 348–9
tender offers, in 361
Federal Trade Commission (FTC) 17
Act (1914) 19–20
powers 20
Federal Reserve System 25
fiduciaries 319, 320, 327, 389
fiduciary duties 52, 226–7, 281, 319
see also directors
breach of 91, 229, 277–8
broad scope of 90
class actions 338, 341–2
enforcing 245
financial advisors, of 277–8
care 5, 89, 228, 389
good faith 89, 91
loyalty 89, 93, 228, 390–91
liability 168, 273, 346
fiduciary outs 53, 219, 221, 224–5, 236, 266–7
no-shop provisions and 220, 255
final period problem 109–10
financial acquirers
financial crisis (2008) 2, 25, 26
financing
see also junk bonds; liquidation preferences
cash 67, 68–9
equity 68
junk bonds, from 23
pension funds, from 23
post-financing valuation 130, 132, 134, 146
pre-financing valuation 130, 133, 134, 146
private 125
staged 129–33
stock 67, 68–9, 137, 146
common 149
preferred 150
venture capital see venture capital
fraud 20, 52, 88, 107, 326, 361
India, in 456
fraudulent misrepresentation 359
free cash flow 69–70
freezeouts 5–6, 285
see also business judgment rule;
self-dealing
business judgment deference in 6
Delaware Court approach to 287–90, 296–7, 299
case law 296–7, 299
empirical evidence 297–9
unified standard 289–90, 297, 299, 300–301
doctrine
convergence 292–6
divergence 290–92
entire fairness reviews, in 287–8, 289, 292–3, 296–7, 300
merger 6, 289
self-dealing in 286, 287–90
tender offer 287–8, 289–90, 292
value-destroying 294
two-step transactions 6
game theory 160, 165
global downturn 25
globalization 25, 26
of knowledge 449
going private 22, 330, 347, 427, 438–9
see also freezeouts
golden parachutes 22, 216, 320, 370
‘Go-Go Sixties’ 354–6
go-shops 42, 61, 220, 222, 232
Great Depression, the 19, 20
greenmail 22, 248
hedge funds 25, 26, 193
see also investors
activist 73, 204, 367–8, 377, 385, 396, 407
multi-strategy 341
hidden ownership 192–3, 194
high frequency trading 366
holdbacks 39, 60–61
horizontal mergers 16, 19, 216
hostile takeovers 21, 22, 26, 216, 248–9,
357, 397, 407
**Index**

see also defences; returns; tender offers, hostile
bidder returns and 72
Canada, in 420–21, 424, 431–2
defense 91–3, 186, 369
two-tier tenders 248–9

**IBP Inc. v. Tyson** 255–8
Indian M&A
agreements 452–3, 455–6
dispute resolution 459–60
due diligence 456–8
earnouts 458–9
escrow 457–8
indemnities 457–8
pricing provisions 458–9
representation 456–7
risk allocation 456–8
warranties 456–7
asset acquisitions 453
challenges in 452–3
concentrated ownership 450–51
corporate law 445
cross-border 448–9, 450, 452
foreign direct investment 451–2
Foreign Exchange Management Act (1999) 451
Foreign Investment Promotion Board (FIPB) 451
growth in 447
legal transplants in 44, 447, 453, 460–61
mergers 453
private 447, 450–52
public 450, 450–52
regulatory framework 451–2
Takeover Code 452
Reserve Bank of India (RBI) 451
Securities and Exchange Board of India (SEBI) 451
share acquisitions 453
takeover rules 452
transactional practice 448–9
–US comparison 445, 450
information
see also earnouts
asymmetry 67, 68, 360–61, 401
earnouts and 156–7, 161–4
transactional failure, and 158–61
private 67
insider trading 391–2, 404
interest rates 25, 26
internationalization 26
see also globalization
investment
see also financing; liquidation preferences; venture capital
bankers see investment bankers
banks 24, 150
investors see investors
long-term 206, 403
short-term 403
syndication 129
investment bankers
conflicts of interest 245, 258–9
fairness opinions 248
investors
see also financing; hedge funds;
investment; shareholder;
stockholder; venture capital
–corporate raiders comparison 397
limiting 404–5
individual 366
institutional 366–7
late stage 124
long-term 396, 398
–short-term conflict 400, 398–400, 401–4, 410
protection for 359–65
short-term 396, 398
activist shareholders as 8
–long-term conflict 398–400, 401–4, 410
venture capital 123, 124
judicial remedies
directors, against 274–7
officers, against 277–8
judicial review 88
deal protection devices, of 225–30
freezeouts, of 287–90
differing standards in 290
standards of 218, 270, 276, 278, 287, 294, 279
unfairness, for 96
Research handbook on mergers and acquisitions

judicial opinions
see also deal protection devices;
defences; litigation
conflicts of interest, on 258–9
deal protection, on 253–5
fairness opinions, on 246–8
MAC clauses, and 255–8
majority-of-the-minority vote (MOM), on 252
poison pills, on 249–51
special committees, on 252–3
two-tiered tender offers, on 248–9
junk bonds 22–3, 248
market crash 23
jurisprudence 217, 431
deal protection 227, 229
business judgment rule deference 88, 97, 226, 236
complete lock-ups 229–30
scrutiny 226–9, 237
standards of 226
freeze-out mergers 138
poison pill 442

Knightian uncertainty 56, 403

legal transplants 44, 445–7, 453, 460–61
letters of intent 33, 52
see also contracts
leveraged buyouts (LBOs) 21, 23, 72, 75
see also buyouts; private equity
bidder returns and 72
boom 13
liability
contractual 52, 60, 454
creditors, to 3
directors’ 5, 83–4, 85, 87, 275–6
environmental 159
fiduciary duty 168, 346
insurance 273
mitigating 247
officer 277
product 105–6, 159, 165
risk 277
standards of 280
successor 104–6, 107–8, 110
liquidation preferences 124–6, 138

see also financing; preferences;
venture capital
enhanced 124, 126, 136–7, 140, 142, 143
fixed return 128, 129, 146
investment syndication, and 129
multiple 144
payment priority 128
preferred stock 125, 126–33, 136, 145
participating 129
structure 126–9
satisfying 127–8
staged financing, and 129–33
start-ups, and 145–50
liquidity 25
bidder returns and 72–3
capital 73
control trade-offs 29, 53
historic growth in 356–7
litigation
see also appraisal; business judgment rule; entire fairness reviews;
judicial opinions; settlement appraisal 335–6, 338–42
class actions 307
agency costs of 325
securities–merger differentiating 328–9
class representatives in, selecting 324–5
developments influenced by 245–6
enhanced scrutiny in 269–71, 321
fairness opinions, and 246–8
fees 305
fee awards 311–13
fee-shifting 306
forum-selection 306, 322
increase in 321–2
lead counsel 328–31
selection criteria 319–20, 328–30
lead plaintiffs 6, 326–8
institutional investor 326–7
selection criteria 20, 324–5
merger 6–7, 305
class litigation, as 307
rationale behind 323
theory behind 320–21
multiforum 322
multijurisdictional 322
Index 475

release 307
risks
deal not closing 321
settlement see settlement
specific performance, for 256
trends in 237

MBCA see Model Business Corporations Act
market constraints 109–10, 111
market efficiency 344–5, 403
efficient capital market hypothesis (ECMH) 400, 401
fundamental, as 403
improving 190
market integration in Europe 26
match rights 42, 49, 61
medium of exchange 25, 67–9
see also financing; returns
cash 67, 68
mixed offers 68
stock 67, 68
mega-deals 23–5, 216, 448
memorialization 30–31
see also contracts
merger of equals 45, 69, 269
merger litigation see litigation, mergers
merger waves 70–74, 216–17
see also conglomerates; leveraged buyouts
conglomerates 71
deregulation and 71–2
industry shocks, and 73
leveraged buyouts 72
liquidity and 72, 73
technological innovation, and 73
minority buyouts see freezeouts
monopolies 13, 17
moral hazard 201, 205
contracts, in 50, 60
managerial 204, 207
post closing 169–70, 174, 176
earnouts, in 171–2

NASDAQ fall 25
net income 170–72
New York Stock Exchange 13, 354–5
no-shops 49, 220, 228, 232, 253, 255

oligopolies 19, 26
Omnicare, Inc. v. NCS Healthcare, Inc. 225, 229–30, 231
overbidding 70
ownership
beneficial 353, 363–5, 368–9, 385, 386
change of 32
dispersed liquid 52
dispersed target 53
hidden 192–3, 194
insider 70
patterns, effects of 52–5
plans 192
threshold 181–2

Pac-Man defenses 22
panic (1873) 13
Paramount Communications, Inc. v. QVC Network, Inc. 203, 268, 269–70, 273
parent-subsidiary mergers see freezeouts
partial acquisitions 45, 46, 51
past performance 69–70
see also defences
decline in 70
flip-in 369
flip-over 369
wolf pack 404
post-closing
consideration 172–6
covenants 42, 53
issues 155–6
‘lemons’ problem 164
moral hazard see moral hazard preferences
enhanced 139, 141
liquidation see liquidation preferences
preferred stock 128
valuation-for-preference see valuation-for-preference theory
preferred stock see also liquidation preferences
conversion points 153
liquidation preferences 145
participating 144
private equity 21–3, 216
see also leveraged buyouts
firms 13, 22–3
LBOs and 23
take-off of 25
private target deals see deals
product liability 105–6, 159, 165
profit maximization 265, 283, 408, 413
proxy contests/fights 184, 251, 358, 359, 367, 385, 386
avoiding 393
regulation 27
early 16–17
industry specific 53
regulatory arbitrage 26
regulatory avoidance 194
releases 6, 307, 314, 315–16
remedies 274–8
see also appraisal; indemnities
indemnification 457
oppression 431
self-help 48–9
stockholder appraisal 335, 336–8
research issues 75–6
returns
abnormal 66
bidder 69–70
negative 68
positive 68
announcement 68
bidder 67–74
activist investors, and 73
diversifying mergers and 71
divestitures, and 71–2
focused mergers and 71
free cash flow, and 69–70
high liquidity, and 72
insider ownership percentage and 70
LBOs, and 72
medium of exchange, and 67–9
overvaluation, and 73
pre-merger company size and 69
pre-merger performance and 69–70
target innovation, and 73–4
enhanced liquidation preferences
increasing 133–9
market 66, 70
on investment (ROI) 128, 132, 140, 142, 143
simple enhanced liquidation preferences, on 138
Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc. 5, 111–13, 265–6, 278–83
controversial, as 263–4
corporate purpose, and 264, 280–81, 282, 283
director selling efforts 266–8
enhanced scrutiny, and 226, 269–71
deal protections, and 253–5
duties 110–14, 226–9, 431–4
lack of remedies under 274–8
directors, against 274–7
officers, against 277–8
reconfiguring 263
scope of 266, 268–9
uncertainty over 271–4
value maximization, and 280–83
risk
allocation 48
beta 108–9
calculating 399
capital asset pricing model (CAPM) 399–400
management 110
-reducing objectives 71
sharing 48–9, 60, 68
transfer 115
roll-ups 24
see also consolidation
safe harbor 97, 288, 348
‘Saturday Night Special’ 7
SEC see Securities and Exchange Commission
securities
see also disclosure
regulation 32, 353
federal 52
Securities Act (1933) 20, 359
Securities and Exchange Commission (SEC) 115, 352
Securities Exchange Act (1934) 20, 359, 368, 435
Section 10(b) 365
Rule 10b-5 361, 362, 364, 365
Section 13(d) 435 see also Williams Act (1968)
Schedule 13D 385–6 see also Williams Act (1968)
  filing 7, 364, 368, 385–6
Schedule 13G 385–6 see also Williams Act (1968)
securities markets 24, 53, 126, 336, 363, 364, 365, 428
self-dealing 109, 111
  Delaware Courts’ approach to 287–90
seller–buyer, statutory distinction 108, 109
settlement 246
  see also litigation
  amendment 323
  approval 236, 308–10
  confirmatory discovery 309
  disclosure-only 305, 313, 322–3
  limiting 315–16
  presumptive no-benefit rule for 314–15
fair and reasonable 308
fee awards 311–13
judicial approach to 306–13
low-value, rejecting as a matter of course 313–14
non-pecuniary relief 305
peppercorn 310
proportionality 315–17
releases 307
  global 316
  proportionality and 315–17
relief 309–10
  scrutiny of 236–7
shareholders
  see also investors; stakeholders;
  stockholder; successor liability
activist 7, 26, 367
  de-staggering of boards, and 204–5
  limiting 404–5
  leading to higher dividends 405
agreements 32
appraisal rights 7, 107
  protecting 106
  restricting 102–3
  creditors, differences in treatment of 106–8
  diversified 108
  dominant 69
employee 192
  fiduciary constraints on 391–4
  individual investors as 254–6
interests, maximizing 5
long-term/short-term conflict 398–400, 401–4, 410
manager conflict 69
minority
  tender offer directly to 286
  protection 290–91, 292
  protection 106, 108–9
  diversification 109
  final period problem 109–10
representatives 51
short-term/long-term conflict 398–400, 401–4, 410
stakeholders, as 192
share purchases to gain control 358
shark repellents 22
Sherman Antitrust Act (1905) 17–19
short-form mergers 286, 288, 293, 437
Siliconix Inc. Shareholders Litigation, In re 288, 290–91, 294, 298
single payment mechanism 159, 161, 164, 171
Smith v. Van Gorkom 5, 246–8
specification 31, 34
  see also contracts
  business 45–7
  price 47–8
  problems 209
  structure, of 45
squeeze-outs see freezeouts
staggered boards see freezeouts
  see also board of directors;
  defenses
  beneficial, as 208
cross-sectional studies on 209–10
decline of 203, 204
detrimental to value, as 203–4, 207
takeover defense, as 184–6, 187–8, 191–2, 202–3
takeover defense, as 184–6, 187–8, 191–2, 202–3
takeover defense, as 184–6, 187–8, 191–2, 202–3
theoretical debate over 205–7, 212
time-series analysis of 210–11
stakeholders
see also investors; shareholder interests 412
shareholders as 192
third party 407–10
corporations having duties towards 407–8
employees as 407, 409
protecting 408
standard of care
business judgment rule as 85, 86–7
standards of review 4–5, 280, 321
see also business judgment rule;
enhanced scrutiny; entire fairness reviews
business judgment rule 2–3, 83
enhanced scrutiny 269–71, 321, 272
entire fairness reviews 251, 329–30
standstills 33, 393
see also contracts
start-ups
see also unicorns
valuation of 123
implied 145–50
statutory mergers 285, 291, 293, 346
see also de facto mergers;
equivalence
equivalence in 100–101
stock
see also liquidation preferences
accumulations 352
capital 143
common 125, 127, 128–9, 130–32
preferred 126–7, 128
conversion points 153
convertible 127, 129–30
repurchases 352
stockholder
see also appraisal; business judgment rule; shareholder
activists 377–8, 380–84, 394
repurchases from 392, 393
threat, as 393–4
appraisal 335–6
controlling 84, 245, 251, 253, 458
transactions 85, 88, 93–5, 97
ratification 95–7
stock market crash 1929 20
see also Great Depression, the
successor liability 104–6, 107–8
claims 110
fraud, on 107
takeover defences see defenses
targets 70
innovation and 73–4
tax inversions 26
tender offers
see also disclosure; Williams Act
boards, and 291
cash 22, 352, 353, 354, 356–8
hostile 359
unregulated 358, 359–60
challenging in court 361–2
check on management performance, as 353
contested 352–3
disclosure, and 352–4
entire fairness reviews, and 291
freezeouts 287–8, 289–90, 292
industrial sabotage, as 352
information asymmetry in 360–61
minority shareholder protection in 290–91
not coercive 288
stock (stock exchanges) 358
third-party 292
two-step 285
two-tier 248–9
unethical, as 357
terms 31, 33, 34
boilerplate 35–8
defined 43–4
express 107
market norms 36
negotiating 285
patterns in 62
protecting parties 408
variation in 37–8, 61–2
time horizon 281
tort law
communications, regulating 52
fraud 20, 52, 88, 107, 326, 361
negligent misrepresentation 52
total return equity swaps (TRS) 115, 116
transactions
see also deals; freezeouts; hostile takeovers; vertical mergers
consideration see consideration
contracts governing see contracts
controlling stockholder 85, 88, 93–5, 97
costs 53, 117, 144, 151, 173, 294, 300–301
cross-border 25, 26, 216, 448–9, 450, 452
enforcing see deal protection devices
equivalence in see equivalence
financing see financing
form 99–100
going private see going private
global 216
importance of 32
negotiating 29, 33, 35–6, 50, 61, 126, 216, 226, 230, 371, 393
arm's length 93–4, 345
MAC clauses 255–8
value 231
problematic 2–3, 26, 96–7
protecting see deal protection devices
regulating 52
structuring 3
transactional surplus 157–8, 159, 161, 174
two-step 6, 337, 350
void 95–6
trusts 13, 16–17, 216, 383
see also antitrust
trustbusters 17, 18
consolidation of industries in 16–17
regulating 17–19

unicorns 3
see also start-ups; valuation
creating 123
investment syndication in 129–33
preferred stock liquidation preferences in 144–5
reputation 213
staged financing in 129–33
valuation 123
skepticism over 123–4, 151
liquidation preferences and 124–5, 145–50
venture capital financing 124–6

Unocal Corp. v. Mesa Petroleum Co.
92–3, 97, 226–9
heightened standard of review 203, 270, 387
intermediate scrutiny 226
two-tier tender offers, and 248–9

valuation
see also start-ups; unicorns
arms-length 129
-for-preference-theory see valuation-for-preference-theory
inflating 124, 150
methodologies 348–9
over 67, 68, 73
post-financing 130, 132, 134, 146
pre-money (pre-financing) 130, 133, 134, 139, 146, 150
reliability of 124
second-best approach 347–8
target 68
valuation-for-preference theory 123–4
economics of 133–45
probability distribution 133, 144
returns 135, 143
liquidation preferences see liquidation preferences
value
see also appraisal; returns; start-ups; unicorns
capital asset pricing model (CAPM) 399–400
discharged cash flow 399
enterprise 125–6, 146
expected, calculating 399
fair 166, 335, 336, 337–8, 345, 347, 437
appraisal, in 7, 348–9
future, discounting 134, 146
gains 66
large transactions destroying 69
maximization 71, 73, 264, 268, 271, 278, 280–81
long-term 281, 282
short-term 269
non-reversible reductions 295
present 134
calculating 348, 399
discharged 206, 400
positive net 295
research handbook on mergers and acquisitions

-reducing freezeouts 294, 295
reported 123, 125–6
synergy 67
true 159, 162–3, 166, 171–2
venture capital
see also financing
financing 124–6, 129, 151
investment syndication, and 129
liquidation preferences see liquidation preferences
staged financing, and 129–33
vertical mergers 19, 216
vetoes 105, 127, 202, 293–4
voidable transactions 95–6
voting
see also defences; hidden ownership agreements 33, 223–4
empty
social positive, as 194
takeover defences, and 191–4
rights 191, 192–4, 425
'universal' majority 204
Williams Act (1968) 7, 352–4, 362–5
see also disclosure; tender offers
10-day reporting window 368
adoption of 359–65
amendment 367–9
future of 370–71
Section 13(d) 363–4
Schedule 13D 364, 385–6
Schedule 13G 385–6
Section 13(e) 364
Section 14(d) 365
Section 14(e) 365
Williams, Senator Harrison A. Jr 352–3
Wilson, President Woodrow 18–19
windfalls 320